Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
Wu HL, Webb GM, Fuchs SP, Pessoa CT, Hwang JM, Fisher HK, McCullen AJ, Humkey MC, Brown MK, Waytashek CM, Boyle CD, Kukula KA, Potter SK, Devlin G, Elmore ZC, Hull JA, Zikos J, Swanson T, Armantrout K, Chun K, Crank H, Bailey L, White R, Barber-Axthelm A, Fischer M, Smedley JV, Axthelm MK, Fennessey CM, Keele BF, Desrosiers RC, Magnani DM, Asokan A, Sacha JB. Adeno-associated virus gene therapy-mediated CCR5 blockade suppresses virus replication long term in SHIV-infected macaques. Sci Transl Med. 2026 Apr 29; 18(847):eadw1976.
-
Hamadeh IS, Merz M, Derkach A, Modelevsky L, Lesokhin AM, Mailankody S, Hultcrantz ML, Tan CR, Hassoun H, Shah UA, Maclachlan K, Rajeeve S, Hashmi H, Maura F, Firestone RS, Wang AX, Amin A, Patel D, Scordo M, Shah GL, Landau HJ, Giralt S, Usmani SZ, Korde N. Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies. Clin Lymphoma Myeloma Leuk. 2026 Jun; 26(6):e802-e810.
-
Porter RL, Zhou Y, Eskndir N, Hayes M, Polak M, Lee EK, Krasner C, Campos S, Wright AA, Liu JF, Stover EH, Sawyer H, Xiong N, Pfaff KL, Rodig SJ, Tayob N, Zweizig S, John V, Veneris J, Matulonis UA, Konstantinopoulos PA. Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial. Nat Commun. 2026 Mar 26; 17(1).
-
Marzo-Ortega H, Navarro-Compan V, Dubreuil M, Mease PJ, Magrey M, Rudwaleit M, D'Agostino MA, Gaffney K, Kay J, de la Loge C, Massow U, Taieb V, Vaux T, Deodhar A. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. 2025 11 28; 11(4).
-
Hamadeh IS, Modelevsky L, Chan A, Mitchell A, Firestone RS, Wang AX, Shekarkhand T, Korde N, Hultcrantz ML, Lesokhin AM, Mailankody S, Hassoun H, Shah UA, Maclachlan K, Rajeeve S, Hashmi H, Patel D, Shah GL, Scordo M, Landau HJ, Giralt S, Usmani SZ, Tan CR. Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses. JCO Oncol Pract. 2026 Jun; 22(6):1105-1111.
-
Xu C, Liang XY, Huang XQ, Jin F, Yang KY, Hu GY, Zhu XD, Wang Y, Huang Y, Zhang N, Hu DS, Guo L, Zou GR, Chen XZ, Xiao SW, Li JG, Shen LF, Li YY, Huang J, Long GX, Li L, Huang L, She LJ, Wu Y, Zeng WH, Qiang MY, Liu WX, Su Y, Tang LL, Xie FY, Han F, Lu LX, Xiang YQ, Mao YP, Li WF, Liu X, Yang Q, Zhou GQ, Guo R, Ouyang PY, Wang XH, Chen L, Liu LT, Lin L, Li JB, Lin AH, Zhao HY, Hong SB, Jie YS, Huang HL, Tang XH, Zeng YC, Yun JP, Zang SB, Du ZM, Ye ZL, Liu LZ, Tian L, Li HJ, Peng YL, Liu N, Li YQ, Liang YL, Wei HM, Chen YP, Zhang Y, Du XJ, Lv JW, Sun Y, Ma J. Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial. JAMA. 2025 Sep 16; 334(11):973-983.
-
Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N. A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2). Int J Gynecol Cancer. 2026 06; 36(6):102654.
-
Meara EM, Curran DL, Wiss K, Plumptre I. Eosinophilic Plastic Bronchitis in a Child With Palmoplantar Psoriasis Treated With Ustekinumab. Pediatr Dermatol. 2026 Jan-Feb; 43(1):163-165.
-
Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi I, Sato T, Shaheen M, Zhao L, Kelley H, Liu H, Kumar S, Bobilev D, Krieg AM, Wooldridge JE, Kirkwood JM. Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025 Aug 01; 131(15):e70022.
-
Meinel TR, B?cke P, D'Anna L, Merlino G, Aguiar de Sousa D, Poli S, Purrucker JC, Strambo D, Romoli M, De Marchis GM, Pfeilschifter W, Zedde M, Marto JP, Candelaresi P, Lemmens R, Scoppettuolo P, Woock M, Kermer P, Kristoffersen ES, Ghannam M, Frol S, Nolte CH, Yakushiji Y, Touz? E, Uphaus T, Mannino M, Ntaios G, Padjen V, Henninger N, Zipser-Mohammadzada F, Mariano ME, Guerreiro C, Burini A, Ceccarelli L, Valente M, Gomez-Exposito A, Kleeberg A, Thevoz G, Michel P, Stufano G, Vlachos D, Herrmann M, Rodrigues B, Spina E, Andreone V, Allardt A, Alshaer QN, Riegler C, Kunieda T, Boulanger M, Hahn M, Papadimitriou D, Muppa J, Maes L, Ranta A, Tyson A, Barber PA, Davis AJ, Wu TY, Kaesmacher J, Fischer U, Seiffge DJ. Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use. Stroke. 2025 Oct; 56(10):2836-2845.